The arrival of the CMS’s Medicare GLP-1 Bridge program has redrawn the map of drug pricing for weight management, setting a new, predictable monthly price point that is rippling across pharmacies, manufacturers, and care models. The Medicare GLP-1 Bridge operates within a Medicare-specific framework that is distinct from commercial insurance markets, so direct comparisons across channels can be challenging. The company serves as both a prescribing provider and comprehensive care coordinator within the Medicare GLP-1 Bridge Program. Commenting on the Bridge program, Joe Nadglowski, the organization’s president and CEO, said, “The Medicare GLP-1 Bridge program is a significant step forward for people living with obesity who have long faced barriers to access under Medicare.” For now, the Bridge’s $50 copay anchors a new baseline in GLP-1 pricing for Medicare beneficiaries.